Top KingWin Ltd. Received Nasdaq Delisting Notice Subject to Hearing Request

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.

POSCO's labor union will launch an indefinite strike starting Nov. 2 after wage talks collapsed. The union demands a 7.1% base pay increase, while management offered 2.5%. POSCO Holdings is expected to report Q3 revenue of 18.6394 trillion won and operating profit of 812.7 billion won, up 8% and 27% YoY, respectively, according to FnGuide. A strike could disrupt production, but management plans to adjust schedules and maintain operations.

Oracle plans to invest $1 billion over four years to expand its partner ecosystem, supporting companies building services across its cloud, database, and applications. The commitment includes training, technical resources, and cloud migration funding. Oracle aims to enhance partner capabilities in AI and other areas, but did not provide specific spending details or targets.